Trial Profile
Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 09 Jan 2024 Planned End Date changed from 21 Mar 2024 to 29 Feb 2024.
- 14 Sep 2022 Planned End Date changed from 11 Mar 2024 to 21 Mar 2024.
- 09 Feb 2021 Results published in the AIDS